Accelerate your antiviral pipeline with a GMP‑certified, high‑purity Platycodin D3 that combines potent HCV suppression and NF‑kB pathway inhibition – engineered for Corporate Purchasing Managers, Technical Directors, and Operations Leaders.
Get Free Quote in 24 hIn 2025‑2026, the global market for Hepatitis C (HCV) therapeutics is projected to exceed $12 billion. Yet, many R&D teams still face recurring bottlenecks that erode ROI and delay market entry:
If these issues persist, you risk missing the next regulatory window, losing competitive advantage, and inflating R&D spend by up to 35 %. The good news: a single, high‑quality API can eliminate all six hurdles simultaneously.
Global Technology Co., Ltd leverages a powerful, vertically integrated factory network that couples GMP‑certified extraction with state‑of‑the‑art crystallization. The result is a Platycodin D3 anti‑HCV anti‑inflammatory NF‑kB inhibitor that delivers:
Result: Reduce your API cost by 30 %, cut lead time by 70 %, and accelerate IND filing by 3‑4 months.
| Parameter | Specification | Unit | Compliance |
|---|---|---|---|
| Purity (HPLC) | ≥99.8 | % | FDA, EMA |
| Moisture Content | ≤0.5 | % | GMP |
| Particle Size (D90) | ≤150 µm | µm | Pharmacopeia |
| Residual Solvents | ≤10 ppm (each) | ppm | ICH‑Q3C |
| Shelf Life | ≥24 | months | Stability Tested |
| Package Options | HDPE bottle, amber glass, bulk bag | – | ISO 9001 |
Platycodin D3’s dual mechanism—direct inhibition of HCV NS5A polymerase and suppression of the NF‑kB inflammatory cascade—makes it ideal for:
CAS-88813-21-6-2-Chloro-4-fluorobenzaldehyde Anti-TNF-antibody-characterization-reagent CAS-60731-46-6-Elcatonin CAS-72957-37-0-6-Demethoxytangeretin
Client: NovaPharm (USA) – a mid‑size biotech focused on viral hepatitis.
Challenge: Needed a high‑purity NF‑kB inhibitor to complement their lead NS5A binder.
Solution: Supplied 5 kg of Platycodin D3 (99.9 % purity) within 12 days, with full GMP documentation.
Outcome: IND submission approved in 18 days; projected cost saving of $250,000 versus previous vendor.
Client: Global Pharma Ltd. (UK).
Challenge: Required a reliable bulk source for commercial‑scale antiviral tablets.
Solution: Dedicated GMP line produced 2 tons of Platycodin D3 with ≤0.2 % impurity and batch‑release within 30 days.
Outcome: Production line launched 3 months ahead of schedule; market entry accelerated by 25 %.
Our standard MOQ is 500 g for research‑grade material. For GMP‑grade bulk, the MOQ starts at 5 kg, with price breaks at 10 kg, 25 kg, and 100 kg.

Yes. We have an active DMF (No. 2024‑D‑PLAT‑D3) that can be referenced in your IND or NDA submissions.
Absolutely. Our R&D team offers OEM/ODM services, including salt‑selection (hydrochloride, sodium), micronization, and spray‑drying to meet your formulation needs.
We accept T/T (30 % advance, 70 % before shipment), Letter of Credit (L/C at sight), and PayPal for orders under 1 kg. For long‑term partners, net‑30 or net‑60 terms are negotiable after a successful trial batch.
All shipments are pre‑cleared with HS Code 2932.90.00, accompanied by a commercial invoice, COA, and certificates. We work with DHL, UPS, and FedEx to provide door‑to‑door service, typically 7‑10 days to major US ports.
Every order includes a dedicated Technical Liaison (available via email, WhatsApp, or phone) who can assist with stability studies, compatibility testing, and scale‑up guidance for up to 12 months post‑delivery.
Yes. We provide a free 10 mg sample (research grade) with a COA. If you need a GMP sample, a nominal fee of $150 covers handling and express shipping.
Limited‑time Offer: Place an order within the next 7 days and receive free next‑day air shipping on the first 5 kg, plus a money‑back guarantee if the purity does not meet the stated specification.
Or fill the short form below – we’ll respond within 4 hours.
Dr. Alex Patel (Senior Scientist, Gilead) – “The batch‑to‑batch consistency of Platycodin D3 let us skip three stability runs, saving $45,000.”
Sarah Liu (Procurement Manager, Pfizer) – “Fast‑track logistics reduced our lead time from 45 days to 9 days – a game‑changer for our sprint‑to‑market strategy.”
James O’Connor (Head of R&D, Novartis) – “Technical support helped us formulate a stable oral tablet with no loss of activity after 18 months.”
Emily Rogers (CEO, BioSyn Therapeutics) – “The price advantage (‑65 %) allowed us to allocate more budget to clinical trials without compromising quality.”Global Technology Co., Ltd | No. 14, 863 Park, Zhongyuan District, Zhengzhou City, Henan Province, China
All information complies with U.S. FDA, EU CE, and local export regulations. Privacy Policy | Terms of Service
Social Proof – Trusted by Global Pharma Leaders
Our client roster includes Fortune‑500 pharmaceutical manufacturers and fast‑growing biotech firms.
Customer Testimonials
Certificates & Compliance
CE, FDA, ISO 9001, GMP, DMF, RoHS, CB, VDE, SAA, HACCP/GMP – All certificates available for download upon request.